Renewal of EBV-hybridoma method: Efficient generation of recombinant fully human neutralizing IgG antibodies specific for tetanus toxin by use of tetroma cells
Affiliations: [a] Department of Biological Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda-shi, Chiba 278-8510, Japan | [b] Second Department of Bacteriology, National Institute of Health, Kamiosaki, Shinagawa-ku, Tokyo 141, Japan | [c] Department of Bacterial Pathogenesis and Infection Control, National Institute for Infectious Disease, 4-7-1 Gakuen, Musashimurayama-shi, Tokyo 208-0011, Japan | [d] Present address: GeneFrontier Co., 3-2-10 Nihonbashi-Kayabacho, Tokyo 103-0025, Japan
Correspondence:
[*]
Corresponding author: Dr. Joe Chiba, Department of Biological Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda-shi, Chiba 278-8510, Japan. Tel./Fax: +81 4 7122 9695; E-mail: chibaj@rs.noda.tus.ac.jp
Abstract: We have generated tetroma cell lines by the fusion of newly developed parental 6JC5.2 cells with a human B cell line, which was transformed with Epstein-Barr virus (EBV) and enriched with antibody-forming cells that produce neutralizing antibodies to tetanus toxin (TT) by a limiting dilution method using IL-6. The resultant two tetroma cell lines stably produced different monoclonal antibodies (mAbs), TT1 (IgG1·λ) and TT2 (IgG4·κ) reactive with TT after three-times consecutive cell cloning. Although weak to almost nonexistent neutralizing activities against TT were detected in TT1 and TT2 mAbs, respectively, mixing of them resulted in a dramatic increase in the neutralizing activity and complete protection from the toxin was observed in vivo. Moreover, functional immunoglobulin (Ig) genes were cloned from at least 10 cells in the first cloning step of tetromas after the cell fusion. None of the endogenous Ig genes, derived from the parental cell that hinders functional Ig gene cloning, was amplified. In addition, the EBV genome derived from the B cells was eliminated from the antibody producing tetroma lines. This classical but revised EBV-hybridoma method using fusion partner 6JC5.2 may become one alternative method for production of fully human antibodies useful for prevention and treatment of infectious diseases and cancer.
